Bausch + Lomb, a US-based developer of eye health products, has received the CE mark for its Technolas Teneo 317 excimer laser workstation, designed to treat all types of ametropia (refractive errors).
The next-generation excimer laser for refractive surgery can be used to treat myopia, hyperopia and astigmatism.
In addition to these traditional LASIK capabilities to treat, the Teneo 317 has integrated Supracor, a corneal approach to treating presbyopia.
Presbyopia is a condition where, with age, the eye exhibits a progressively diminished ability to focus on near objects.
Supracor's unique multifocal ablation profile and sophisticated algorithm provide the expected near addition, while minimising the induction of undesired aberrations within the pupil.
Supracor is a new generation of bilateral presbyopia treatment that can give patients the spectacle free lifestyle.
The Teneo 317 is the second femtosecond laser to be introduced by the company for supporting cataract and corneal procedures on a single platform.
With the enhanced ergonomic design and layout, the Teneo 317 offers more comfortable and relaxing surgical experience to the patients.
Bausch + Lomb Technolas president and chairman of Laser and Surgical Strategy and Development Dr Kristian Hohla said: "The system features advanced ergonomics and a compact footprint, allowing it to easily integrate into any practice."
In January 2013, Bausch + Lomb formed formed Bausch + Lomb Technolas, after the acquisition of Technolas Perfect Vision, ophthalmology laser company based in Munich, Germany.
According to GlobalData estimates, Excimer Lasers market in Europe which was valued at $74m in 2012 is expected to grow at a CAGR of 2.9% to reach a value of $90m by 2019.
Image:Bausch + Lomb headquarters in New York. Photo: courtesy of Daniel Penfield.